# Urogen Pharma (URGN): value investors who own it | moatshark

1 value investor held Urogen Pharma in their Q3 2026 13F, led by Polen Capital Management. See who bought, sold and how ownership has changed by quarter.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Polen Capital Management | 0.0% | $1.1m | New | 1 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-10-08 | Degnan Chris | Chief Financial Officer | Sold | 2202 | $81k |
| 2026-09-08 | Smith Jason Drew | General Counsel | Sold | 1519 | $65k |
| 2026-09-08 | Schoenberg Mark | Chief Medical Officer | Sold | 871 | $37k |
| 2026-08-20 | Schoenberg Mark | Chief Medical Officer | Sold | 60677 | $2.9m |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/urgn). Values traded and returns are estimates. Not investment advice. Built 2026-10-21.